Protocol Ledger

NCT04115293 · Phase III · COMPLETED

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Interventional Phase III clinical trial protocol NCT04115293 sponsored by UCB in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-17 Enrollment: 174 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04115293
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)174 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04115293
Protocol FieldVerified Registry Value
NCT IdentifierNCT04115293
Consolidated Lead SponsorUCB
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment174 participants (ACTUAL)
Registered Start Date2019-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI